Cost-effectiveness analyses of targeted oral anti-cancer drugs: A systematic review

Medicine and Dentistry

• Cost-Effectiveness Analysis 100%
• Systematic Review 100%
• Anticarcinogen 100%
• Oral 100%
• Malignant Neoplasm 92%
• Health Care Cost 23%
• Cancer 15%
• Health Technology 15%
• Technology Assessment 15%
• Clinical Trial 7%
• Oncology 7%
• Intravenous Drug Administration 7%
• English (Language) 7%
• Cancer Localization 7%
• Effectiveness Study 7%

Keyphrases

• Anticancer Drugs 100%
• Cost-effectiveness Analysis 100%
• Oral Anticancer Agents 100%
• Treatment Setting 16%
• Health Technology Assessment 16%
• Literature Search 8%
• Clinical Trials 8%
• National Institutes of Health 8%
• High Cost 8%
• Exclusion Criteria 8%
• Cancer Site 8%
• English Language 8%
• Advanced Stage 8%
• Oncology 8%
• Standard of Care 8%
• PubMed 8%
• Assessment Programs 8%
• Head-to-head Comparison 8%
• Economic Evaluation 8%
• Conflict of Interest 8%
• Cochrane Library 8%
• Community Practice 8%
• Assessment Report 8%
• Off-label Indications 8%
• Non-adherence 8%
• Risk of Bias 8%
• Site Type 8%
• US FDA 8%
• Payers 8%
• Second-line Therapy 8%
• Cost-effectiveness Study 8%
• Original Research Article 8%
• Intravenous Therapy 8%
• Treatment Lines 8%